ETNB

8.75 +0.29 (+3.37%)

89bio Inc · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website 89bio.com
Employees(FY) 45
ISIN US2825591033

Performance

+5.29%

-18.38%

+13.78%

+3.18%

+11.89%

YTD

-30.61%

Profile

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The company's lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.

1M 3M 6M YTD 1Y 2Y

Advanced Technical Analysis

Technical Analysis of ETNB 2025-03-14

The stock's indicators reflect a neutral sentiment, with the Moving Average Score at 50 indicating stability, while the Oscillators and Technical Scores at 45 and 47 suggest a lack of momentum. Overall, these scores imply that the stock is currently in a consolidation phase, with no strong bullish or bearish signals.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of ETNB

QualityGrowthMomentumValue4

Stock Rank

Recent News & Updates

2025-03-12 23:34
Citi says SMid biotechs alternative to large caps as it starts coverage(Yahoo Finance)
2025-03-11 21:55
Bears are Losing Control Over 89BIO (ETNB), Here's Why It's a 'Buy' Now(Yahoo Finance)
2025-03-03 03:05
89bio to Participate in the Leerink Partners Global Healthcare Conference(Globenewswire)
2025-02-27 03:05
89bio Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates(Globenewswire)
2025-02-19 20:55
Wall Street Analysts See a 171.42% Upside in 89BIO (ETNB): Can the Stock Really Move This High?(Yahoo Finance)
2025-02-19 20:55
Should You Buy 89BIO (ETNB) After Golden Cross?(Yahoo Finance)
2025-02-06 06:45
Institutional investors have a lot riding on 89bio, Inc. (NASDAQ:ETNB) with 58% ownership(Simply Wall St.)
2025-02-06 03:05
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(Globenewswire)
2025-02-03 11:16
89bio Closes $287.5 Million Public Offering(MT Newswires)
2025-02-03 08:00
89bio Announces Closing of its Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares(GlobeNewswire)
2025-02-02 19:00
89bio Announces Closing of its Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares(Globenewswire)
2025-01-28 22:31
89bio, Inc. Announces Pricing of $250.0 Million Public Offering of Common Stock and Pre-Funded Warrants(GlobeNewswire)
2025-01-28 16:59
Why 89bio Stock Lagged the Market Today(Motley Fool)
2025-01-28 09:31
89bio, Inc. Announces Pricing of $250.0 Million Public Offering of Common Stock and Pre-Funded Warrants(Globenewswire)
2025-01-27 16:24
Akero Therapeutics Stock Doubles — Pulling 89bio Higher — On Positive MASH Study(Investor's Business Daily)
2025-01-27 16:12
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants(GlobeNewswire)
2025-01-27 03:12
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants(Globenewswire)
2025-01-24 06:51
Daily – Vickers Top Buyers & Sellers for 01/24/2025(Argus Research)
2025-01-13 08:00
89bio Provides Business Update and Outlook for 2025(GlobeNewswire)
2025-01-12 19:00
89bio Provides Business Update and Outlook for 2025(Globenewswire)
2025-01-07 03:17
New Strong Sell Stocks for January 7th(Zacks)
2024-12-19 16:05
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(GlobeNewswire)
2024-12-19 03:05
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(Globenewswire)
2024-12-04 13:02
Why Is 89bio, Inc. (ETNB) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds?(Insider Monkey)
2024-11-29 13:30
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(GlobeNewswire)
2024-11-29 00:30
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(Globenewswire)
2024-11-26 16:05
89bio to Participate in the 7th Annual Evercore HealthCONx Conference(GlobeNewswire)
2024-11-26 03:05
89bio to Participate in the 7th Annual Evercore HealthCONx Conference(Globenewswire)
2024-11-15 08:05
89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting® 2024(GlobeNewswire)
2024-11-14 19:05
89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting 2024(Globenewswire)

Page 1 of 4

previousnext

Disclaimer: The information provided here and on kavout.com is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout makes no recommendations regarding investment decisions based on this information. You are solely responsible for your investments. Please conduct your own research and consult qualified financial advisors before investing. Past performance does not guarantee future results.